Corvus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CEORichard A. Miller
CEORichard A. Miller
Employees28
Employees28
HeadquartersBurlingame, California
HeadquartersBurlingame, California
Founded2014
Founded2014
Employees28
Employees28
CRVS Key Statistics
Market cap93.13M
Market cap93.13M
Price-Earnings ratio-3.07
Price-Earnings ratio-3.07
Dividend yield—
Dividend yield—
Average volume133.05K
Average volume133.05K
High today$1.90
High today$1.90
Low today$1.75
Low today$1.75
Open price$1.81
Open price$1.81
Volume137.17K
Volume137.17K
52 Week high$4.19
52 Week high$4.19
52 Week low$1.03
52 Week low$1.03
CRVS News
Seeking Alpha 1d
Corvus stock gains amid pricing of $30.6M direct offeringShares of Corvus Pharmaceuticals (NASDAQ:CRVS) rose 6% in morning trading Thursday after the company priced a $30.6M registered direct offering. Corvus said it...
TipRanks 1d
Corvus Pharmaceuticals announces pricing of $30.6M registered direct offeringCorvus Pharmaceuticals has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregat...